Login / Signup

Potassium-lowering effects of sodium-zirconium cyclosilicate in the early post-transplant period.

William ShockeyJoshua J WiegelSandesh ParajuliNeetika GargKurtis J SwansonDidier A Mandelbrot
Published in: Clinical transplantation (2023)
This study represents the largest investigation on the use of SZC in transplant recipients. A single 10-g dose of SZC reduced serum K+ levels in all subgroups, while the use of adjunctive K+-lowering therapies did not provide additional reduction beyond the effects of SZC. Importantly, no gastrointestinal complications were observed. These findings suggest that SZC may be a safe and promising therapeutic option for hyperkalemia management following solid organ transplantation.
Keyphrases
  • risk factors
  • stem cells
  • cell therapy
  • bone marrow
  • mesenchymal stem cells